07:00 , Sep 24, 2012 |  BC Week In Review  |  Company News

Boehringer Ingelheim infectious news

Boehringer said it will discontinue its virology research program following a review of its research areas and priorities. The company said, "the demands for medical innovation are shifting significantly" in virology due to the availability...
00:39 , Sep 20, 2012 |  BC Extra  |  Company News

Boehringer discontinues virology research program

Boehringer Ingelheim GmbH (Ingelheim, Germany) said it will discontinue its virology research program following a review of its research areas and priorities. The company said, "The demands for medical innovation are shifting significantly" in virology...
07:00 , Aug 15, 2011 |  BC Week In Review  |  Company News

Boehringer Ingelheim infectious news

Boehringer will extend and expand price reduction and rebate programs for its HIV drugs to AIDS Drug Assistance Programs (ADAPs). The agreement with the ADAP Crisis Task Force (ACTF) extends rebates mandated by health reform...
07:00 , Aug 1, 2011 |  BC Week In Review  |  Company News

Boehringer Ingelheim, Bristol-Myers infectious news

The Medicines Patent Pool said it began negotiations for patents to HIV drugs from Boehringer and Bristol-Myers. The pool, established last year by UNITAID, allows companies to obtain a license to market generic versions of...
07:00 , Apr 4, 2011 |  BC Week In Review  |  Company News

Gilead, Abbott, Boehringer Ingelheim, Bristol-Myers, GlaxoSmithKline, J&J, Merck, Pfizer, Roche infectious news

California State Controller John Chiang sent letters to eight companies requesting they extend and expand existing supplemental price reduction and rebate program for its HIV/AIDS drugs with California's AIDS Drug Assistance Program (ADAP). The Controller...
07:00 , Sep 7, 2009 |  BioCentury  |  Strategy

A rare breed

A rare breed Approval date Company Drug Indication 12/24/08 Ferring Pharmaceuticals A/S Firmagon degarelix acetate Advanced prostate cancer 8/15/08 Prestwick Pharmaceuticals Inc. (A) Xenazine tetrabenazine...
07:00 , May 4, 2009 |  BC Week In Review  |  Clinical News

Aptivus tipranavir regulatory update

EMEA's CHMP issued a positive opinion to extend the indication for Aptivus tipranavir from Boehringer Ingelheim to include the treatment of HIV in highly pre-treated adolescents aged 12 and older resistant to multiple protease inhibitors...
07:00 , Jun 30, 2008 |  BC Week In Review  |  Clinical News

Aptivus tipranavir regulatory update

FDA approved an sNDA for Aptivus tipranavir capsules for use in combination with ritonavir for treatment-experienced pediatric patients aged 2-18 years, which will be available shortly. The capsule formulation of the non-peptidic protease inhibitor (PI)...
07:00 , Jun 12, 2008 |  BC Innovations  |  Targets & Mechanisms

Eyeing New Uses for Protease Inhibitors

A paper in the Journal of Clinical Investigation indicates that HIV protease inhibitors could be repurposed as neuroprotectants to block apoptosis in age-related macular degeneration, diabetic retinopathy and other conditions involving neuronal apoptosis.1 The findings...
07:00 , Jun 9, 2008 |  BC Week In Review  |  Company News

Gilead, Boehringer Ingelheim, AIDS Healthcare Foundation sales and marketing update

According to the foundation, Gilead and Boehringer committed to suspend increases in the prices of their HIV drugs for government agencies. The foundation wrote to nine companies to request price freezes in March. The foundation...